Mangkawat
liked
$HOOKIPA Pharma (HOOK.US)$
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
Poolbeg Pharma and HOOKIPA Pharmahave provided an update on their potential combination, following announcements from January 2 and 7, 2025. The key update concerns Gilead Sciences' participation in the proposed concurrent Fundraise. Gilead has expressed its intention to:
1. Vote in alignment with HOOKIPA Board's recommendation if a formal offer ...
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
Poolbeg Pharma and HOOKIPA Pharmahave provided an update on their potential combination, following announcements from January 2 and 7, 2025. The key update concerns Gilead Sciences' participation in the proposed concurrent Fundraise. Gilead has expressed its intention to:
1. Vote in alignment with HOOKIPA Board's recommendation if a formal offer ...
2
Mangkawat
liked
$BioLine Rx (BLRX.US)$ I lost 6k sell all and moved to other no eye see
2
Mangkawat
commented on
$OrangeKloud Technology (ORKT.US)$
If you has been scamed, don't sell at this price. The scammer short at high and they have to buy back at low.
If you has been scamed, don't sell at this price. The scammer short at high and they have to buy back at low.
2
13
Mangkawat
commented on
27
10
7
$NVIDIA (NVDA.US)$ have gpu and cpu ? what happen when inaguration new president next week? share your tough.
Mangkawat
commented on
$Jupiter Neurosciences (JUNS.US)$ As long as it holds the 8.50 support which it has bounced off of 3 times it is headed to 20.00. Buy in 8.55. Sell 20.00. Stop-loss 8.49. Easiest stop-loss to set because if it falls below 8.50 during market hours it is going to fall down to the low.
9
12
Mangkawat
liked
$Lipella Pharmaceuticals (LIPO.US)$
Jonathan Kauffman used to owned 18.6% of the stock in 2022. The change to 16.2% was based on the increase in total outstanding shares of LIPO which consequently dilutes the percentage shares held by exising shareholders even if the number of shares owned stayed the same.
So this is not considered a catalyst for me. IMO
Jonathan Kauffman used to owned 18.6% of the stock in 2022. The change to 16.2% was based on the increase in total outstanding shares of LIPO which consequently dilutes the percentage shares held by exising shareholders even if the number of shares owned stayed the same.
So this is not considered a catalyst for me. IMO
3